Oscar Gruss Issues Angiogenesis Report

NEW YORK, March 21 /PRNewswire/ -- The following is being issued by Oscar
Gruss & Son Incorporated, a member of the National Association of Securities
Dealers, CRD number 2091: 
Oscar Gruss & Son Incorporated has issued an in-depth biotechtechnology
review entitled "Trends in Therapeutic Angiogenesis Inhibition." 
Author Akhtar Samad, M.D., Ph.D., senior equity research analyst at Oscar
Gruss, provides a detailed examination of emerging strategies for targeted
disruption of blood flow by inhibition of new and existing blood vessels.  Dr.
Samad expects such therapies to have large market applications in cancer,
inflammation, ophthalmic diseases, cardiovascular diseases and skin diseases.
Although he does not yet see clear evidence of an emerging dominant leader in
this field, Dr. Samad believes anti-angiogenesis approaches will find broad
use as monotherapies and in combination with traditional therapies. 


    Companies discussed in this report include:
    AstraZeneca (London: AZN)
    Bayer (Frankfurt: BAY)
    Boston Life Sciences (Nasdaq: BLSI)
    British Biotech (London: BBG)
    Cellgene (Nasdaq: CELG)
    Collagenex (Nasdaq: CGPI)
    Entremed (Nasdaq: ENMD)
    Genentech (NYSE: DNA)
    ImClone (Nasdaq: IMCL)
    Maganin (Nasdaq: MAGN)
    OxiGene (Nasdaq: OXGN)
    Regeneron (Nasdaq: REGN)
    Ribozyme (Nasdaq: RZYM)
    Warner-Lamber (NYSE: WLA)


Clients of Oscar Gruss wishing to get a copy of this report should contact
their broker. 
This report is based upon information which Oscar Gruss & Son Incorporated
(Oscar Gruss) believes to be reliable.  However, neither Oscar Gruss nor any
individual acting on the behalf of Oscar Gruss can guarantee the accuracy or
completeness of its contents.  It does not purport to contain a complete
analysis of every material fact concerning any company, industry or security,
and further information is available upon request.  Oscar Gruss assumes that
it will be read in conjunction with other available reports and data.
Opinions expressed herein are subject to change without notice.  No investor
can assume that reliance on the views, opinions or recommendations contained
herein will produce profitable results.  Oscar Gruss makes a market in this
security, and may have a long or short position in this security.  Oscar Gruss
and/or our employees and affiliates may have positions in securities which are
referred to herein and may make purchases or sales thereof while this report
is in circulation.  Oscar Gruss or one of its affiliates may from time to time
perform investment banking or other services for, or solicit investment
banking or other business from a company mentioned in this report.
Foreign-currency-denominated securities are subject to fluctuations in
currency exchange rates that could have a positive or adverse effect on an
investor's return upon the conversion into local currency of dividends or
interest received, or proceeds from the sale of such securities.  In addition,
the value of U.S. dollar-denominated ADRs and the value of U.S.
dollar-denominated ordinary shares, or common shares, of foreign issuers can
be influenced by fluctuations in currency exchange rates.
 

SOURCE  Oscar Gruss & Son Incorporated 


   
 
Press spacebar to pause and continue. Press esc to stop.